 |
Title
|
|
|
|
Phase 
|
|
|
|
Protocol IDs
|
|
|
| |
Doxorubicin Hydrochloride Liposome or Capecitabine as First-Line Chemotherapy in Treating Women With Metastatic Breast Cancer
|
|
|
|
Phase IV
|
|
|
|
SPRI-P04445
EU-20654, NCT00266799, SPRI-PELICAN
|
|
| |
Effects of Granulocyte Colony-Stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function
|
|
|
|
Phase III, Phase II
|
|
|
|
D-0140
NCT00169104
|
|
| |
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
|
|
|
|
Phase III, Phase II
|
|
|
|
20050113
NCT00243685
|
|
| |
Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer
|
|
|
|
Phase III
|
|
|
|
IBCSG-27-02
BIG-1-02, EU-20320, NCT00074152, NSABP-B-37, EUDRACT-2005-001484-64
|
|
| |
Anastrozole With or Without Fulvestrant as First-Line Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer
|
|
|
|
Phase III
|
|
|
|
SWOG-S0226
CAN-NCIC-MAC7, S0226, NCT00075764
|
|
| |
Breast Cancer Trial of an Investigational Drug versus Capecitabine in Male or Female Patients with Advanced Breast Cancer
|
|
|
|
Phase III
|
|
|
|
XRP9881B/3001
NCT00081796
|
|
| |
A Study of Docetaxel Monotherapy or DOXIL®/CAELYX® and Docetaxel in Patients With Advanced Breast Cancer
|
|
|
|
Phase III
|
|
|
|
DOXIL-BCA-3001
NCT00091442
|
|
| |
Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine in Patients With Metastatic Breast or Colorectal Cancer
|
|
|
|
Phase III
|
|
|
|
MDA-CCC-0326
MDA-2005-0328, NCT00305643
|
|
| |
E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes and Refractory to the Most Recent Chemotherapy
|
|
|
|
Phase III
|
|
|
|
E7389-G000-301
NCT00337103
|
|
| |
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
|
|
|
|
Phase III
|
|
|
|
NCCTG-N0574
N0574, ACOSOG-N0574, NCT00377156
|
|
